(Source: NYSE Euronext Inc) NYSE Euronext welcomes Cardio3 BioSciences on its European market Cardio3 BioSciences is the first Belgian company raising capital through an IPO in both Belgium and France Brussels, 5 July 2013- Cardio3 BioSciences, a leading Belgian biotechnology specialized in the treatment of cardiac diseases, today celebrated its successful listing on NYSE Euronext (NYX) in Brussels and Paris. Cardio3 BioSciences is the first Belgian company to launch a public offering simultaneously on NYSE Euronext in Brussels and Paris. Cardio3 BioSciences, headquartered in Mont-Saint-Guibert (Belgium), is a biopharmaceutical company, founded in 2007, and focused on the development of...
↧